Safety and tolerability of empagliflozin in patients with Type 2 diabetes

被引：0
|
作者：
Salsali, A. [1 ]
Kohler, S. [2 ]
Hantel, S. [3 ]
Kim, G. [2 ]
Woerle, H. J. [2 ]
Broedl, U. C. [2 ]
机构：
[1] Boehringer Ingelheim Pharmaceut Inc, Therapeut Area Metab, 90 E Ridge POB 368, Ridgefield, CT 06877 USA
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Therapeut Area Metab, Ingelheim, Germany
[3] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
来源：
DIABETIC MEDICINE | 2016年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P106
引用
收藏
页码：66 / 66
页数：1
相关论文
共 50 条
  • [1] Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes
    Kohler, Sven
    Salsali, Afshin
    Hantel, Stefan
    Kaspers, Stefan
    Woerle, Hans J.
    Kim, Gabriel
    Broedl, Uli C.
    CLINICAL THERAPEUTICS, 2016, 38 (06) : 1299 - 1313
  • [2] Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
    Kinduryte Schorling, Ona
    Clark, Douglas
    Zwiener, Isabella
    Kaspers, Stefan
    Lee, Jisoo
    Iliev, Hristo
    ADVANCES IN THERAPY, 2020, 37 (08) : 3463 - 3484
  • [3] Pooled Safety and Tolerability Analysis of Empagliflozin in Patients with Type 2 Diabetes Mellitus
    Ona Kinduryte Schorling
    Douglas Clark
    Isabella Zwiener
    Stefan Kaspers
    Jisoo Lee
    Hristo Iliev
    Advances in Therapy, 2020, 37 : 3463 - 3484
  • [4] Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes (T2DM)
    Kohler, Sven
    Salsali, Afshin
    Hantel, Stefan
    Kim, Gabriel
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2015, 64 : A302 - A303
  • [5] Population Pharmacokinetics and Exposure–Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes
    Kyle T. Baron
    Sreeraj Macha
    Uli C. Broedl
    Valerie Nock
    Silke Retlich
    Matthew Riggs
    Diabetes Therapy, 2016, 7 : 455 - 471
  • [6] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
    Heise, Tim
    Seman, Leo
    Macha, Sreeraj
    Jones, Peter
    Marquart, Alexandra
    Pinnetti, Sabine
    Woerle, Hans J.
    Dugi, Klaus
    DIABETES THERAPY, 2013, 4 (02) : 331 - 345
  • [7] Population Pharmacokinetics and Exposure-Response (Efficacy and Safety/Tolerability) of Empagliflozin in Patients with Type 2 Diabetes
    Baron, Kyle T.
    Macha, Sreeraj
    Broedl, Uli C.
    Nock, Valerie
    Retlich, Silke
    Riggs, Matthew
    DIABETES THERAPY, 2016, 7 (03) : 455 - 471
  • [8] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of Empagliflozin in Patients with Type 2 Diabetes Mellitus
    Tim Heise
    Leo Seman
    Sreeraj Macha
    Peter Jones
    Alexandra Marquart
    Sabine Pinnetti
    Hans J. Woerle
    Klaus Dugi
    Diabetes Therapy, 2013, 4 : 331 - 345
  • [9] Safety and tolerability of combinations of empagliflozin/linagliptin for 52 weeks in subjects with type 2 diabetes
    Kohler, S.
    Patel, S.
    DeFronzo, R. A.
    Lewin, A.
    Liu, D.
    Kaste, R.
    Woerle, H. -J.
    Broedl, U.
    DIABETOLOGIA, 2015, 58 : S363 - S363
  • [10] Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical Trials
    Sven Kohler
    Cordula Zeller
    Hristo Iliev
    Stefan Kaspers
    Advances in Therapy, 2017, 34 : 1707 - 1726
12345